Published in Blood on July 02, 2013
MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin (2014) 1.40
New insights into monoclonal B-cell lymphocytosis. Biomed Res Int (2014) 1.36
MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood (2014) 1.19
Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ (2014) 1.18
MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med (2013) 1.05
Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer (2016) 0.99
Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML. Sci Rep (2015) 0.95
Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood (2015) 0.95
Molecular pathways: microRNAs, cancer cells, and microenvironment. Clin Cancer Res (2014) 0.95
Immunomodulatory role of microRNAs transferred by extracellular vesicles. Biol Cell (2015) 0.94
Prognostic value of miR-21 in various cancers: an updating meta-analysis. PLoS One (2014) 0.93
Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine (2015) 0.92
Physiological roles of miR-155. Immunology (2015) 0.89
MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression. PLoS One (2014) 0.89
New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. Int J Mol Sci (2016) 0.86
Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood (2015) 0.86
The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med (2015) 0.85
Current Role of Genetics in Hematologic Malignancies. Indian J Hematol Blood Transfus (2015) 0.84
A potential regulatory loop between Lin28B:miR‑212 in androgen-independent prostate cancer. Int J Oncol (2014) 0.83
Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget (2015) 0.83
MicroRNAs, Major Players in B Cells Homeostasis and Function. Front Immunol (2014) 0.83
The oncogenic MicroRNA Hsa-miR-155-5p targets the transcription factor ELK3 and links it to the hypoxia response. PLoS One (2014) 0.83
Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia. Mol Med (2015) 0.83
Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma. Oncotarget (2016) 0.82
Role of Extracellular Vesicles in Hematological Malignancies. Biomed Res Int (2015) 0.81
Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma. Int J Clin Exp Med (2014) 0.81
microRNA: Diagnostic Perspective. Front Med (Lausanne) (2015) 0.80
CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p. PLoS One (2015) 0.80
MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci (2017) 0.78
miR-155 as a Biomarker in B-Cell Malignancies. Biomed Res Int (2016) 0.78
Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J (2016) 0.78
Novel mechanisms of regulation of miRNAs in CLL. Trends Cancer (2016) 0.77
Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res (2016) 0.76
Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biol Med (2016) 0.76
MicroRNAs in Myeloid Hematological Malignancies. Curr Genomics (2015) 0.76
Tumor-Associated CSF MicroRNAs for the Prediction and Evaluation of CNS Malignancies. Int J Mol Sci (2015) 0.76
Role of microRNA in chronic lymphocytic leukemia onset and progression. J Hematol Oncol (2015) 0.76
Microbiomarkers with big impact in CLL. Blood (2013) 0.75
MicroRNAs as biomarkers in leukemia. Stem Cell Investig (2014) 0.75
Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. Ann Hematol (2016) 0.75
CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D. Leukemia (2016) 0.75
MicroRNAs, DNA Damage Response, and Cancer Treatment. Int J Mol Sci (2016) 0.75
MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem (2009) 40.90
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
microRNAs: tiny regulators with great potential. Cell (2001) 11.23
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature (2010) 5.73
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med (2008) 5.48
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) (2011) 4.64
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood (2007) 3.64
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood (2011) 2.34
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J (2000) 2.34
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One (2009) 1.97
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood (2011) 1.96
Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia (2010) 1.76
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood (2011) 1.75
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood (2009) 1.61
Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program (2010) 1.58
Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens. Blood (2006) 1.58
miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol (2008) 1.48
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol (2009) 1.48
MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2011) 1.43
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer (2010) 1.28
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol (2009) 1.27
Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood (2009) 1.21
Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood (2011) 1.09
In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clin Cancer Res (2012) 0.89
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
MicroRNAs in Cancer. Annu Rev Med (2009) 9.37
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
MicroRNA expression and function in cancer. Trends Mol Med (2006) 7.02
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med (2002) 6.33
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Systematic review of depression, anxiety, and other indicators of psychological distress among U.S. and Canadian medical students. Acad Med (2006) 5.82
Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res (2006) 5.72
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56
MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer (2009) 5.47
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood (2005) 5.21
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study. JAMA (2006) 5.06
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A (2002) 4.86
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood (2010) 4.51
Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol (2012) 4.44
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
Relationship between burnout and professional conduct and attitudes among US medical students. JAMA (2010) 4.34
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A (2007) 4.06
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell (2008) 4.01
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
Burnout and suicidal ideation among U.S. medical students. Ann Intern Med (2008) 3.96
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw (2008) 3.82
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 3.79
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75